Table 1.

Baseline Characteristics of ART-Naive Adults Living With Human Immunodeficiency Virus and Starting Their First ART Regimen While Receiving Clinical Care, United States, 1999–2015

Characteristic	CNICS Cohort Target Sample   (n = 8,291)		Randomized Clinical Trials Sample   (n = 3,949)
	No.	%	No.	%
Sex
Female	1,451	18	716	18
Male	6,840	82	3,233	82
Race/ethnicity
Hispanic	1,138	14	880	22
Non-Hispanic Black	3,010	37	1,408	36
Non-Hispanic White	3,621	44	1,544	39
Othera	446	5	112	3
Missing datab	76	0.9	5	0.1
Age, years
Medianc	38 (30–45)		38 (31–44)
Ranged	18–78		18–77
Pretreatment CD4 cell count, cells/μL
Medianc	251 (95–394)		212 (76–324)
Ranged	0–1,670		0–1,336
Missing datab	99	1.2	4	0.1
HIV-1 RNA load, log10 copies/mL
Medianc	4.78 (4.21–5.31)		4.72 (4.38–5.22)
Ranged	2.30–7.85		2.26–7.04
Missing datab	0	0	1	0.03
History of AIDS diagnosis
Yes	1,642	20	694	18
No	6,649	80	3,255	82
History of injection drug use
Yes	1,306	16	380	10
No	6,860	84	3,569	90
Missing datab	125	1.5	0	0
Positive for HBV or HCV
Yes	1,430	17	461	12
No	6,861	83	3,488	88
Prescription for antidepressants
Yes	1,464	19	509	13
No	6,363	81	3,440	87
Missing datab	464	5.6	0	0

Abbreviations: AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; CNICS, Centers for AIDS Research Network of Integrated Clinical Systems; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV-1, human immunodeficiency virus type 1.

^a Asian, Native American (American Indian), Alaska Native, Asian/Pacific Islander, Pacific Islander, multiracial (>1 race), and those who reported their race as “other.”

^b Missing data were not included in the category percentage calculations.

^c Values are presented as median (interquartile range).

^d Values are presented as range (minimum–maximum).